Home > Riviste > International Angiology > Fascicoli precedenti > International Angiology 2018 February;37(1) > International Angiology 2018 February;37(1):59-63



Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo



International Angiology 2018 February;37(1):59-63

DOI: 10.23736/S0392-9590.17.03886-X


lingua: Inglese

Drug-coated balloons reduce the risk of recurrent restenosis in arteriovenous fistulas and prosthetic grafts for hemodialysis

Nicola TROISI 1 , Pierfrancesco FROSINI 1, Chiara SOMMA 2, Eugenio ROMANO 1, Azzurra GUIDOTTI 1, Pietro C. DATTOLO 2, Giuseppe FERRO 2, Emiliano CHISCI 1, Stefano MICHELAGNOLI 1

1 Department of Surgery, Unit of Vascular and Endovascular Surgery, San Giovanni di Dio Hospital, Florence, Italy; 2 Department of Medicine, Unit of Nephrology and Dialysis, Santa Maria Annunziata Hospital, Bagno a Ripoli, Florence, Italy


BACKGROUND: Aim of this study was to evaluate the early and mid-term outcomes of drug-coated balloons (DCBs) in hemodialysis patients with recurrent stenosis of arteriovenous fistula and previously treated with plain balloon angioplasty (PBA).
METHODS: Between July 2013 and June 2016 38 hemodialysis patients with recurrent stenosis of arteriovenous fistula underwent endovascular treatment with a DCB at our center. All patients were previously treated at the target lesion with a PBA. The intervals in months between the standard PBA and the procedure with DCB (time PBA-DCB) and between the procedure with DCB and the restenosis at the target lesion (time DCB-restenosis) were evaluated and compared with T-test. Estimated outcomes at 2 years in terms of patient survival, primary patency, primary assisted patency, secondary patency, and freedom from target lesion restenosis were assessed with Kaplan-Meier curves.
RESULTS: Intraprocedural technical success was obtained in 97.4% of the cases. During the follow-up (mean duration 14.3 months, range 2-33) 19 patients (50%) developed a restenotic lesion at the target lesion with an estimated 2-year freedom from target lesion restenosis of 32.8%. Mean time PBA-DCB was 6.4 months, and the mean time DCB-restenosis was 7.9 months with a statistically significant difference at T-test (P<0.001). Estimated 2-year rates of primary patency, primary assisted patency, and secondary patency were 40.8%, 73.1%, and 82.5%, respectively.
CONCLUSIONS: In our experience DCBs were safe and effective in the treatment of recurrent stenosis in patients with failing arteriovenous fistula. The time to restenosis at the target lesion was longer respect to that necessary to have a recurrent restenosis after PBA.

KEY WORDS: Arteriovenous fistula - Renal dialysis - Treatment outcome

inizio pagina